

Edgar Filing: Immune Design Corp. - Form SC 13G

Immune Design Corp.
Form SC 13G
October 06, 2017

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. _____) *
Immune Design Corp. (Name of Issuer)
Common Stock
(Title of Class of Securities)
45252L103 (CUSIP Number)
September 29, 2017

(Date of Event which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant
to which this Schedule is filed:

- ? Rule 13d-1(b)
- ? Rule 13d-1(c)
- ? Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 45252L103

13G

Page 2 of 8

1.

NAMES OF REPORTING PERSONS

Bain Capital Public Equity Management, LLC

2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(see instructions)

- (a) ?
- (b) ?

Edgar Filing: Immune Design Corp. - Form SC 13G

3.

SEC USE ONLY

4.

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH

5.

SOLE VOTING POWER

1,299,013

6.

SHARED VOTING POWER

0

7.

SOLE DISPOSITIVE POWER

1,299,013

8.

SHARED DISPOSITIVE POWER

0

9.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

Edgar Filing: Immune Design Corp. - Form SC 13G

1,299,013

10.

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(see instructions) ?

11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

5.07%

12.

TYPE OF REPORTING PERSON (see instructions)

PN

CUSIP No. 45252L103

13G

Page 3 of 8

1.

NAMES OF REPORTING PERSONS

Brookside Capital Investors II, L.P.

2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(see instructions)

(a) ?

Edgar Filing: Immune Design Corp. - Form SC 13G

(b) ?

3.

SEC USE ONLY

4.

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH

5.

SOLE VOTING POWER

1,299,013

6.

SHARED VOTING POWER

0

7.

SOLE DISPOSITIVE POWER

1,299,013

8.

SHARED DISPOSITIVE POWER

0

Edgar Filing: Immune Design Corp. - Form SC 13G

9.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

1,299,013

10.

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(see instructions) ?

11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

5.07%

12.

TYPE OF REPORTING PERSON (see instructions)

PN

CUSIP No. 45252L103

13G

Page 4 of 8 Pages

1.

NAMES OF REPORTING PERSONS

Brookside Capital Trading Fund, L.P.

2.

Edgar Filing: Immune Design Corp. - Form SC 13G

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(see instructions)

- (a) ?
- (b) ?

3.

SEC USE ONLY

4.

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH

5.

SOLE VOTING POWER

1,299,013

6.

SHARED VOTING POWER

0

7.

SOLE DISPOSITIVE POWER

1,299,013

8.

SHARED DISPOSITIVE POWER

0

Edgar Filing: Immune Design Corp. - Form SC 13G

9.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

1,299,013

10.

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(see instructions) ?

11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

5.07%

12.

TYPE OF REPORTING PERSON (see instructions)

PN

CUSIP No. 45252L103

13G

Page 5 of 8

Item 1.

(a)

Name of Issuer

The name of the issuer to which this filing on Schedule 13G
relates is Immune Design Corp. (the "Company")

Edgar Filing: Immune Design Corp. - Form SC 13G

(b)

Address of Issuer's Principal Executive Offices

The principal executive offices of the Company are located at
1616 Eastlake Ave. E, Suite 310, Seattle WA 98102

Item 2.

(a)

Name of Person Filing

This Statement is being filed on behalf the following (collectively,
the "Reporting Persons"): Brookside Capital Trading Fund, L.P., a
Delaware limited partnership ("Trading Fund"), whose sole general
partner is Brookside Capital Investors II, L.P., a Delaware limited
partnership ("Brookside Investors II"), whose sole general partner
is Bain Capital Public Equity Management, LLC, a Delaware limited
liability company ("BCPE Management").

The Reporting Persons have entered into a Joint Filing Agreement,
dated October 6, 2017, a copy of which is filed with this Schedule
13G as Exhibit A, pursuant to which the Reporting Persons have agreed
to file this statement jointly in accordance with the provisions of
Rule 13d-1(k)(1) under the Securities Exchange Act of 1934.

(b)

Address of the Principal Office or, if none, residence

The principal business address of each of the Trading Fund, Brookside
Investors II and BCPE Management is c/o Bain Capital Public Equity, LP,
200 Clarendon Street, Boston, MA 02116.

(c)

Citizenship

Each of the Trading Fund, Brookside Investors II and BCPE Management
is organized under the laws of the State of
Delaware.

(d)

Title of Class of Securities

The class of equity securities of the Company to which this filing on
Schedule 13G relates is Common Stock
("Common Stock").

(e)

CUSIP Number

The CUSIP number of the Company's Common Stock is 45252L103.

Edgar Filing: Immune Design Corp. - Form SC 13G

Item 3. If this statement is filed pursuant to 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a)

?

Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

(b)

?

Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

(c)

?

Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

(d)

?

Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

(e)

?

An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E);

(f)

?

An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F);

(g)

?

A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G);

Edgar Filing: Immune Design Corp. - Form SC 13G

(h)

?

A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i)

?

A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j)

?

Group, in accordance with 240.13d-1(b)(1)(ii)(J).

[x] If this statement is filed pursuant to 240.13d-1(c), check this box.
Item 4. Ownership.

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

(a)

Amount beneficially owned: 1,299,013.

(b)

Percent of class: 5.07% based upon 25,619,732 shares of Common Stock outstanding.

(c)

Edgar Filing: Immune Design Corp. - Form SC 13G

Number of shares as to which the person has: 1,299,013.

(i)

Sole power to vote or to direct the vote: 1,299,013.

(ii)

Shared power to vote or to direct the vote: 0.

(iii)

Sole power to dispose or to direct the disposition of: 1,299,013.

(iv)

Shared power to dispose or to direct the disposition of: 0.

Item 5. Ownership of Five Percent or Less of a Class.

Not applicable.

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not applicable.

Item 7. Identification and Classification of the Subsidiary Which

Acquired the Security Being Reported on By the Parent

Holding Company.

Not applicable.

Item 8. Identification and Classification of Members of the Group.

Not applicable.

Item 9. Notice of Dissolution of Group.

Not applicable.

Item 10. Certification.

Edgar Filing: Immune Design Corp. - Form SC 13G

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

CUSIP No. 45252L103

13G

Page 7 of 8

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: October 6, 2017

BAIN CAPITAL PUBLIC EQUITY MANAGEMENT, LLC

By:

Name: Joshua Ross

Title: Managing Director

BROOKSIDE CAPITAL INVESTORS II, L.P.

By: Bain Capital Public Equity Management, LLC,
its general partner

By:

Name: Joshua Ross

Title: Managing Director

BROOKSIDE CAPITAL TRADING FUND, L.P.

By: Brookside Capital Investors II, L.P.,
its general partner

By: Bain Capital Public Equity Management, LLC,
its general partner

By:

Name: Joshua Ross

Edgar Filing: Immune Design Corp. - Form SC 13G

Title: Managing Director

Exhibit A

AGREEMENT REGARDING THE JOINT FILING OF
SCHEDULE 13G

The undersigned hereby agree as follows:

(i) The Statement on Schedule 13G, and any amendments thereto, to which this Agreement is annexed as Exhibit A is and will be filed on behalf of each of them in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended; and

(ii) Each of them is responsible for the timely filing of such Schedule 13G and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accuracy of the information concerning the other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate.

Dated: October 6, 2017
BAIN CAPITAL PUBLIC EQUITY MANAGEMENT, LLC

By:
Name: Joshua Ross
Title: Managing Director

BROOKSIDE CAPITAL INVESTORS II, L.P.
By: Bain Capital Public Equity Management, LLC,
its general partner

By:
Name: Joshua Ross
Title: Managing Director

BROOKSIDE CAPITAL TRADING FUND, L.P.
By: Brookside Capital Investors II, L.P.,
its general partner
By: Bain Capital Public Equity Management, LLC,
its general partner

By:
Name: Joshua Ross
Title: Managing Director

The percentage of Common Stock reported owned by the Reporting Persons is based upon 25,619,732 shares of Common Stock outstanding as reported

Edgar Filing: Immune Design Corp. - Form SC 13G

in the Issuer's Quarterly Report on Form 10-Q dated June 30, 2017.

The percentage of Common Stock reported owned by the Reporting Persons is based upon 25,619,732 shares of Common Stock outstanding as reported in the Issuer's Quarterly Report on Form 10-Q dated June 30, 2017. The percentage of Common Stock reported owned by the Reporting Persons is based upon 25,619,732 shares of Common Stock outstanding as reported in the Issuer's Quarterly Report on Form 10-Q dated June 30, 2017.

48220740_1

48220740_1

48220740_1

48220740_1